PLANO, Texas, Feb. 29, 2016 -- AREVA Med, with roots in France and the U.S., has selected two top design schools – French École Supérieure de Design Troyes and U.S. Art Institute Dallas Texas – to work on key elements of its new high-purity lead-212 (212Pb) production facility under construction in Plano, Texas.
|
||||||
Five teams composed of 35 students from both schools will work on design proposals for the lobby, conference room, and “monument sign” in front of the building. AREVA Med will assess the projects and select the best design for this state-of-the-art facility. The winning team will see the results of their project at the opening ceremony.
Patrick Bourdet, CEO of AREVA Med said: “This project is symbolic of AREVA Med’s innovative and collaborative spirit and, demonstrates our commitment to the local community and our willingness to facilitate exchanges between people from different cultures. This is also an excellent way for students to work on a real project and see the tangible results of their accomplishments.”
Heather Carter, Interior Design Program Coordinator at the Art Institute of Dallas, said: “Understanding global perspectives is one of the professional standards our students must meet as part of our interior design program. This collaboration with French peers will give our students an opportunity to develop their knowledge of another culture and they are excited to work with other programs and nations in blended teams. It is a very positive undertaking, and we appreciate AREVA Med for initiating it.”
Séverine Nomdedeu, Director of École Supérieure de Design Troyes, added: “Managing practical projects is at the heart of our strategy. Made possible by AREVA Med, the collaboration with the Art Institute of Dallas represents a tremendous opportunity to exchange, share, and create, and is in line with the transcultural opening that we hope to bring to our students and the way we teach design.”
More information at www.arevamed.com, http://www.groupe-esc-troyes.com/, and https://www.artinstitutes.edu/dallas/Programs/Interior-Design/447
More about AREVA Med
AREVA Med is the AREVA Group medical subsidiary formed in 2009 to develop new therapies to fight cancer. AREVA Med has developed a unique process to extract lead-212 (212Pb), a rare metal used in targeted alpha therapy (TAT), a novel approach which targets and destroys cancer cells, while limiting the impact on nearby healthy cells. AREVA Med collaborates with world-renowned scientific partners, and formed a strategic global alliance with Roche in 2012, to create a new advanced alpha radioimmunotherapy platform. For more information: www.arevamed.com. Follow @AREVAmed on Twitter.
Press Contacts AREVA Med Alison Tise (301) 841-1673 [email protected] @AREVAmed


Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership
CMOC to Acquire Equinox Gold’s Brazilian Mines in $1 Billion Deal to Expand Precious Metals Portfolio
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 



